Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Elanco issued a press release on June 27, 2024, “announc[ing] updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. The press release stated that Zenrelia is expected to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024. The Company had previously set a launch timeline for the third quarter of 2024. The press release also stated that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024, while the Company had previously set an approval timeline for the third quarter of 2024. Following this news, Elanco’s stock price dropped 11% the same day.
| Ticker Symbol | Company Name | Join Deadline | Join |
|---|---|---|---|
| SUI | Sun Communities, Inc. | February 10, 2025 | Join |
| SAVA | Cassava Sciences, Inc. | February 10, 2025 | Join |
| APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
| BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
| PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
| NVO | Novo Nordisk A/S | March 25, 2025 | Join |
| GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
| NEM | Newmont Corporation | April 01, 2025 | Join |